Search clinical trials for: teriflunomide

Total 62 results

Sanofi

Active, not recruiting

Relapsing Forms of Multiple Sclerosis (RMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168) (GEMINI 1) (GEMINI 1)

Relapsing Multiple Sclerosis

Spain, United States, Mexico, Japan, Austria, Belarus, Bulgaria, Canada, China, Czechia, Denmark, Estonia, Finland, Germany, Italy, Lithuania, Poland, Romania, Russian Federation, Sweden, Taiwan, Turkey, Ukraine, Hong Kong
Novartis Pharmaceuticals

Completed

Efficacy and Safety of Ofatumumab Compared to Teriflunomide in Patients With Relapsing Multiple Sclerosis. (ASCLEPIOS II)

Relapsing Multiple Scelrosis

United States, Austria, Belgium, Croatia, Germany, Taiwan, Canada, Czechia, Spain, Argentina, Australia, Peru, South Africa, United Kingdom, Bulgaria, Latvia, Lithuania, Russian Federation, India, Portugal, Italy, Turkey, Finland, France and more
Sanofi

Completed

Long Term Safety and Efficacy Study of Teriflunomide 7 mg or 14 mg in Patients With Relapsing-Remitting Multiple Sclerosis

Multiple Sclerosis

United States, Austria, Canada, Chile, Czech Republic, Denmark, Estonia, Finland, France, Germany, Italy, Netherlands, Norway, Poland, Portugal, Russian Federation, Sweden, Switzerland, Turkey, Ukraine, United Kingdom
Sanofi

Active, not recruiting

Relapsing Forms of Multiple Sclerosis (RMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168) (GEMINI 2) (GEMINI 2)

Relapsing Multiple Sclerosis

United States, Argentina, Belgium, Brazil, Canada, Chile, Croatia, Czechia, France, Germany, Greece, Hungary, India, Israel, Korea, Republic of, Latvia, Netherlands, Norway, Portugal, Puerto Rico, Russian Federation, Serbia, Slovakia, Spai... and more
Sanofi

Completed

Long Term Safety and Efficacy of Teriflunomide (HMR1726) in Multiple Sclerosis With Relapses

Multiple Sclerosis

Canada, France
Novartis Pharmaceuticals

Completed

Efficacy and Safety of Ofatumumab Compared to Teriflunomide in Patients With Relapsing Multiple Sclerosis (ASCLEPIOS I)

Relapsing Multiple Sclerosis

Belgium, Italy, United States, Croatia, Spain, Netherlands, Switzerland, Thailand, Israel, Czechia, Estonia, Poland, France, Bulgaria, Russian Federation, Germany, Turkey, Slovakia, Australia, Denmark, Greece, Argentina, India, Hungary, United Kingdom and more
Sanofi

Completed

Study of Teriflunomide in Reducing the Frequency of Relapses and Accumulation of Disability in Patients With Multiple Sclerosis (TEMSO)

Multiple Sclerosis

Ukraine, Russian Federation, Estonia, Czech Republic, Denmark, Finland, France, Turkey, United Kingdom, United States, Portugal, Austria, Canada, Chile, Germany, Italy, Netherlands, Norway, Poland, Sweden, Switzerland
Oslo University Hospital

Recruiting

Teriflunomide vs. Placebo During Gluten Challenge in Celiac Disease

Celiac Disease

Norway
National Institute of Mental Health (NIMH)

Terminated

Does Enhanced Glutamate Transporter Function Produce Antidepressant Effects in People With Major Depression?

Depression

United States
Sanofi

Completed

To Evaluate the Safety and Efficacy of Teriflunomide in Patients With Relapsing Forms of Multiple Sclerosis (SAFE)

Relapsing Multiple Sclerosis

India
Providence Health & Services
Multiple Sclerosis Center of Northeastern New York

Completed

MAIN STUDY: SWITCH SUB-STUDY: SWITCH-JCV

Multiple Sclerosis

United States
Jan Lycke

Completed

Teriflunomide Concentration in Serum and Cerebrospinal Fluid From Patients With Multiple Sclerosis

Multiple Sclerosis, Pharmacokinetics

Sweden
Sanofi

Completed

An Observational Study on Teriflunomide-exposed Pregnancies

Multiple Sclerosis

United States, Canada
Sanofi

Completed

Evaluation of the Relationship Between ABCG2 Mutation and Teriflunomide Exposure and Safety in Chinese RMS Patients Treated With Teriflunomide 14 mg Once Daily for 24 Weeks (TERI-PK)

Multiple Sclerosis

China
Sanofi

Completed

Safety and Efficacy of Teriflunomide (HMR1726) in Multiple Sclerosis With Relapses

Multiple Sclerosis

Canada, France
Merck Healthcare KGaA, Darmstadt, Germany, an affiliate...
EMD Serono Research & Development Institute, Inc.

Active, not recruiting

Study of Evobrutinib in Participants With RMS (evolutionRMS 2)

Relapsing Multiple Sclerosis

United States, Belarus, Brazil, Bulgaria, Canada, France, Germany, Greece, India, Italy, Latvia, Lithuania, Malaysia, Moldova, Republic of, Norway, Philippines, Poland, Portugal, Puerto Rico, Romania, Russian Federation, Saudi Arabia and more
Merck Healthcare KGaA, Darmstadt, Germany, an affiliate...
EMD Serono Research & Development Institute, Inc.

Active, not recruiting

Study of Evobrutinib in Participants With RMS (evolutionRMS 1)

Relapsing Multiple Sclerosis

United States, Argentina, Australia, Austria, Belgium, Bosnia and Herzegovina, Bulgaria, Canada, Colombia, Croatia, Czechia, Estonia, Finland, France, Georgia, Germany, Hong Kong, Hungary, India, Israel, Italy, Korea, Republic of, M... and more
Centre Hospitalier Universitaire de Nice
Genzyme, a Sanofi Company

Completed

Randomized, Double-blinded Study of Treatment:Teriflunomide, in Radiologically Isolated Syndrome (TERIS)

Multiple Sclerosis

Turkey, France, Switzerland
Actelion

Completed

Oral Ponesimod Versus Teriflunomide In Relapsing MUltiple Sclerosis (OPTIMUM)

Multiple Sclerosis

United States, Belarus, Bosnia and Herzegovina, Bulgaria, Canada, Croatia, Czechia, Finland, France, Georgia, Germany, Greece, Hungary, Israel, Italy, Latvia, Lithuania, Mexico, Poland, Portugal, Romania, Russian Federation, Serbia, S... and more
Sanofi

Completed

A Study to Evaluate the Pharmacokinetic Profiles of Single 14 mg Teriflunomide Tablet in Healthy Chinese Volunteers

Multiple Sclerosis

China
Sanofi

Completed

Phase II Study of Teriflunomide as Adjunctive Therapy to Glatiramer Acetate in Subjects With Multiple Sclerosis

Multiple Sclerosis

United States, Canada, Germany, United Kingdom, Austria, Italy
Derrick Scott Robertson
University of South Florida; Genzyme, a Sanofi Company

Terminated

Rapid Elimination Procedure of Teriflunomide With Colestipol Hydrochloride (TERCOL)

Healthy Volunteers | Teriflunomide Elimination

United States
Sanofi

Completed

Pharmacokinetic and Tolerability Study of 14 mg Single Dose of Teriflunomide in Subjects With Severe Renal Impairment

Renal Impairment

Germany
Sanofi

Completed

Phase II Study of Teriflunomide as Adjunctive Therapy to Interferon-beta in Subjects With Multiple Sclerosis

Multiple Sclerosis

United States, Canada, Germany, Spain, Italy
Sanofi

Completed

Effect of Teriflunomide on Immune Cell Subsets in the Blood of Patients With Multiple Sclerosis (TERI-DYNAMIC)

Multiple Sclerosis

Belgium, Germany, Netherlands
Sanofi

Terminated

Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis and Treated With Interferon-beta (TERACLES)

Multiple Sclerosis Relapse

Spain, Germany, Sweden, Canada, Austria, Korea, Republic of, Russian Federation, Greece, Hungary, Italy, Belgium, Slovakia, Tunisia, France, Australia, United States, Argentina, Brazil, Chile, Colombia, Denmark, Estonia, Finland, Lith... and more
Sanofi

Completed

Study to Investigate the Immune Response to Influenza Vaccine in Patients With Multiple Sclerosis on Teriflunomide (TERIVA)

Multiple Sclerosis

Germany, Ukraine, Canada, Austria, Russian Federation
University of Michigan

Completed

Mechanistic Studies of Teriflunomide in RRMS

Relapsing Remitting Multiple Sclerosis

United States
Centre Hospitalier Universitaire de Nice

Completed

A Study to Evaluate the Safety of Long Term Treatment With Teriflunomide 14 mg Once Daily in Patients With a First Clinical Episode Suggestive of Multiple Sclerosis in a Long-term Extension Period (TERICIS)

Multiple Sclerosis

France
McGill University

Completed

Biomarkers and Disease Activity in Patients Treated With Teriflunomide (Aubagio)

Multiple Sclerosis, Relapsing-Remitting

Canada
Peking University People's Hospital

Recruiting

Teriflunomide for Steroid-resistant/Relapse Immune Thrombocytopenia

Immune Thrombocytopenia

China
National Institute of Neurological Disorders and...

Recruiting

Teriflunomide in HTLV-1 Associated Myelopathy/Tropical Spastic Paraparesis

HAM/TSP

United States
Centre hospitalier de l'Université de Montréal...
Genzyme, a Sanofi Company; Montreal Neurological Institute and Hospital

Completed

Teriflunomide Observational Effectiveness Study

Relapsing Remitting Multiple Sclerosis

Canada
Genzyme, a Sanofi Company

Active, not recruiting

Efficacy, Safety and Pharmacokinetics of Teriflunomide in Pediatric Patients With Relapsing Forms of Multiple Sclerosis (TERIKIDS)

Multiple Sclerosis

Belgium, United States, Bulgaria, Canada, China, Estonia, France, Greece, Israel, Lebanon, Lithuania, Morocco, Netherlands, Portugal, Russian Federation, Serbia, Spain, Tunisia, Turkey, Ukraine, United Kingdom
Biocad

Recruiting

An International, Multicenter, Randomized, Double-Blind, Double-Masked Study of the Efficacy and Safety of BCD-132 (JSC BIOCAD, Russia) Using an Active Reference Drug (Teriflunomide) for the Treatment of Patients With Multiple Sclerosis (MIRANTIBUS)

Multiple Sclerosis

Russian Federation
Sanofi

Completed

An Efficacy Study of Teriflunomide in Participants With Relapsing Multiple Sclerosis (TOWER)

Multiple Sclerosis

Belgium, United States, Australia, Austria, Belarus, Canada, Chile, China, Czech Republic, Estonia, France, Germany, Greece, Mexico, Netherlands, Philippines, Poland, Romania, Slovakia, Spain, Sweden, Thailand, Tunisia, Turkey, Ukraine, United...
Hoffmann-La Roche

Active, not recruiting

A Study to Evaluate the Efficacy and Safety of Fenebrutinib Compared With Teriflunomide in Relapsing Multiple Sclerosis (RMS) (FENhance)

Relapsing Multiple Sclerosis

United States, Mexico, Hungary, China, Germany, Italy, Peru, Poland, Portugal, Russian Federation, Spain, Switzerland, Ukraine, Tunisia, Netherlands, Argentina, Georgia, Hong Kong, Kenya, Dominican Republic, Finland, North Macedonia, Serb...
Sanofi

Recruiting

A Study to Investigate Long-term Safety and Tolerability of Tolebrutinib in Participants With Multiple Sclerosis.

Relapsing Multiple Sclerosis | Secondary Progressive Multiple Sclerosis | Progressive Relapsing Multiple Sclerosis

Belgium
University at Buffalo

Completed

Teriflunomide Tecfidera LMCE

Tecfidera | Teriflunomide

United States
Sanofi

Completed

Phase III Study With Teriflunomide Versus Placebo in Patients With First Clinical Symptom of Multiple Sclerosis (TOPIC)

Multiple Sclerosis

United States, Australia, Austria, Bulgaria, Canada, Chile, Czech Republic, Denmark, Estonia, Finland, France, Germany, Hungary, Lithuania, Mexico, Poland, Romania, Russian Federation, Turkey, Ukraine, United Kingdom
University of California, San Diego

Withdrawn

Examination of Whether Host Preconditioning Modifies Short-term Transplant Survival

Eczema | Atopic Dermatitis

United States
Hoffmann-La Roche

Active, not recruiting

Study to Evaluate the Efficacy and Safety of Fenebrutinib Compared With Teriflunomide in Relapsing Multiple Sclerosis (RMS) (FENhance 2)

Relapsing Multiple Sclerosis

United States, Korea, Republic of, India, Brazil, Poland, Canada, Bulgaria, United Kingdom, France, Greece, Italy, Russian Federation, Turkey, Mexico, Austria, Denmark, Guatemala
Sanofi

Completed

Long Term Safety of Teriflunomide When Added to Interferon-Beta or Glatiramer Acetate in Patients With Multiple Sclerosis

Multiple Sclerosis

United States, Canada, Germany, Italy, Spain, United Kingdom, Austria
Biocad

Active, not recruiting

Comparative Study of the Efficacy and Safety of BCD-132 With Teriflunomide and Placebo in Multiple Sclerosis

Multiple Sclerosis

Russian Federation
TG Therapeutics, Inc.

Completed

Study to Assess the Efficacy and Safety of Ublituximab in Participants With Relapsing Forms of Multiple Sclerosis (RMS) (ULTIMATE II)

Relapsing Multiple Sclerosis (RMS)

United States
McMaster University
National Heart, Lung, and Blood Institute (NHLBI); Canadian Institutes of Health...

Completed

Caffeine for Apnea of Prematurity-Sleep (CAP-S) Study (CAP-S)

Apnea of Prematurity

Australia, Canada
Sanofi

Completed

Using Patient Reported Outcomes (PROs) to Evaluate Teriflunomide Treatment in Relapsing Multiple Sclerosis (RMS) Patients (TERI-PRO)

Multiple Sclerosis

Finland, Belgium, Spain, Chile, Norway, Italy, United States, Austria, Canada, France, Germany, Greece, Sweden, United Kingdom
IMPULS Endowment Fund

Completed

Czech Pharmaco-epidemiological Study on Disease Modifying Drugs (CPE)

Multiple Sclerosis

Czechia
Novartis Pharmaceuticals

Recruiting

Open Label Randomized Multicenter to Assess Efficacy & Tolerability of Ofatumumab 20mg vs. First Line DMT in RMS (STHENOS)

Multiple Sclerosis

Germany, Spain, Italy, France, United Kingdom
Peking University People's Hospital
Peking University First Hospital; Beijing Friendship Hospital; Chinese PLA General... and other collaborators

Recruiting

The Combination of Teriflunomide and Danazol for Steroid-resistant/Relapse Immune Thrombocytopenia

Immune Thrombocytopenia

China

Search clinical trials for: teriflunomide

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Türkiye

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations